A behavioural evaluation of the potential of nNOS inhibitors to control dyskinesia in animal models of Parkinson's disease
Long-term dopaminergic therapy in Parkinson’s disease (PD) can lead to motor complications including dyskinesia which can be treated with amantadine, an N-methyl-D-aspartate (NMDA) receptor antagonist. NMDA receptor activation is linked with nitric oxide (NO) production and changes in synaptic plast...
| Main Author: | |
|---|---|
| Published: |
King's College London (University of London)
2012
|
| Subjects: | |
| Online Access: | http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.628180 |